Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Global Wellness Times.
Press releases published on April 22, 2025
Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader
GlobeNewswire
·
April 22, 2025
Data from the BroADen Phase 1b atopic dermatitis (AD) patient trial expected to be reported in 4Q25 Completed SAD/MAD dosing in KT-621 Phase 1 healthy volunteer trial with data to be reported in June 2025 Two parallel Phase 2b trials in AD and asthma …
Axsome Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire
·
April 22, 2025
NEW YORK, April 22, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in four upcoming …
Standard BioTools Schedules First Quarter Earnings Conference Call on May 6, 2025
GlobeNewswire
·
April 22, 2025
SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report first quarter 2025 financial results on Tuesday, May 6, 2025, after market close. The company will host a conference …
Quantum Biopharma Announces Advocate Against Naked Short Selling and Stock Manipulation, Kevin Malone Appointed as Board Advisor
GlobeNewswire
·
April 22, 2025
TORONTO, April 22, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is pleased to announce the appointment of Kevin Malone as an advisor to the Board of Directors. Mr. Malone …
Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy
GlobeNewswire
·
April 22, 2025
Breakthrough Device Designation (“BDD”) applies to an estimated U.S. population of over 7.7 million patients with uncontrolled hypertension and increased cardiovascular risk BDD also encompasses pacemaker-indicated patients with uncontrolled hypertension …
Rapport Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire
·
April 22, 2025
BOSTON and SAN DIEGO, April 22, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for …
The Scotts Miracle-Gro Foundation Joins with Keep America Beautiful to Announce Martin Luther King Corridor Community Grants for Earth Day
GlobeNewswire
·
April 22, 2025
MARYSVILLE, Ohio, April 22, 2025 (GLOBE NEWSWIRE) -- To help increase the creation of community gardens and green spaces in underserved areas, The Scotts Miracle-Gro Foundation has joined Keep America Beautiful's 2025 Martin Luther King Corridor Community …
Medicenna to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
GlobeNewswire
·
April 22, 2025
TORONTO and HOUSTON, April 22, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune …
Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody
GlobeNewswire
·
April 22, 2025
- Initiation of Upcoming Phase 1a/1b Clinical Trial Expected in the Second Quarter of 2025 - WAYNE, Pa, April 22, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel …
Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)
GlobeNewswire
·
April 22, 2025
TORONTO, April 22, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the University Health Network (UHN) Research Ethics Board has granted approval for Toronto General …
BioNTech veröffentlicht am 5. Mai 2025 Ergebnisse für das erste Quartal 2025 und informiert über operativen Fortschritt
GlobeNewswire
·
April 22, 2025
MAINZ, Deutschland, 22. April 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) wird am Montag, den 5. Mai 2025, die Ergebnisse für das erste Quartal 2025 veröffentlichen. Darüber hinaus wird das Unternehmen am selben …
BioNTech to Report First Quarter 2025 Financial Results and Corporate Update on May 5, 2025
GlobeNewswire
·
April 22, 2025
MAINZ, Germany, April 22, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2025 on Monday, May 5, 2025. Additionally, the Company will host a conference call and …
Tonic Greens Reviews (URGENT) Is It Legit And Safe for Consumers? Ingredients, Benefits, And Side Effects!
GlobeNewswire
·
April 22, 2025
HONOLULU, Hawaii, April 22, 2025 (GLOBE NEWSWIRE) -- Tonic Greens is a multi-functional health supplement that can naturally enhance health and wellness by optimizing the immune functions of the body. The immune system functions only when the body is under …
AscellaHealth Demonstrates Leadership in Realizing the Full Potential of Novel Therapies and Medicinal Products at Advanced Therapies Integrates North 2025
GlobeNewswire
·
April 22, 2025
DUBLIN and BERWYN, Pa., April 22, 2025 (GLOBE NEWSWIRE) -- AscellaHealth, a global partner delivering customisable solutions to support the specialty pharmaceutical industry, proudly announces its participation in Advanced Therapies Integrates North 2025, …
R3 Vascular Announces First Patient Treated in ELITE-BTK Pivotal Trial for Below-the-Knee PAD Using MAGNITUDE® Drug Eluting Bioresorbable Scaffold
GlobeNewswire
·
April 22, 2025
MOUNTAIN VIEW, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), is pleased to announce …
Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines
GlobeNewswire
·
April 22, 2025
New manufacturing and supply agreement with FUJIFILM Diosynth Biotechnologies in North Carolina will enable additional production of Regeneron’s biologic medicines and support high-paying jobs in the region Regeneron’s ongoing and planned investments in …
Best Tips How to Lose Weight Fast with Mitolyn Purple Peel Pills
GlobeNewswire
·
April 22, 2025
New York City, April 22, 2025 (GLOBE NEWSWIRE) -- How to Lose Weight Fast Without Diet or Exercise (2025 Guide): The Mitolyn Purple Peel Pill That's Going Viral Introduction: The Truth About Fast Weight Loss Let's be honest—when most people search for how …
Nourix Sverige Bluff (UPDATED Nourix Avis 2025) Matas Pris en Pharmacie, Trustpilot Recensioner, UK Reviews, Danmark & France Official Website
GlobeNewswire
·
April 22, 2025
AMSTERDAM, April 22, 2025 (GLOBE NEWSWIRE) -- Nourix Avis - Effective and healthy weight loss is a typical struggle in an environment where well-being and health are of utmost importance. A lot of people are always searching for the next great thing in the …
PrimeBiome Reviews: “Gut–Skin Miracle” or Just Hype? Expert Insights
GlobeNewswire
·
April 22, 2025
St. Petersburg, Florida, April 22, 2025 (GLOBE NEWSWIRE) -- With over 19,000 customer reviews and rising buzz across wellness communities, Prime Biome is being hailed as a “gut–skin miracle”—but does it actually live up to the hype? Touted as a dual-action …
Prime Biome Reviews 2025: Updated Comprehensive Guide to the Revolutionary Gut & Skin Health Supplement!
GlobeNewswire
·
April 22, 2025
St. Petersburg, Florida, April 22, 2025 (GLOBE NEWSWIRE) -- Explore how PrimeBiome is transforming gut and skin health in 2025. This detailed review covers everything—from ingredients and expert opinions to real customer experiences—to help you decide if …